Patents by Inventor Wouter Van't Hof
Wouter Van't Hof has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11197889Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: GrantFiled: November 6, 2017Date of Patent: December 14, 2021Assignees: ABT Holding Company, Oregon Health & Science UniversityInventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
-
Publication number: 20210346429Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: ApplicationFiled: July 12, 2021Publication date: November 11, 2021Applicants: ABT Holding Company, Oregon Health & Science UniversityInventors: Richard MAZIARZ, Magdalena KOVACSOVICS, Philip STREETER, Robert DEANS, Wouter VAN'T HOF
-
Publication number: 20210254010Abstract: Methods for isolating mesenchymal stromal cells from umbilical cord blood. The methods include providing a blood collection bag having raw umbilical cord blood contained therein, draining the umbilical cord blood from the blood collection bag, introducing a cell detachment solution into the blood collection bag to dissociate mesenchymal stromal cells adhered to the bag surface, thereby forming a mesenchymal stromal cell enriched fluid, and voiding the mesenchymal stromal cell enriched fluid into a collection apparatus for further processing and culturing.Type: ApplicationFiled: May 31, 2019Publication date: August 19, 2021Inventors: Mary Laughlin, Jeong-Su Do, Wouter Van't Hof
-
Publication number: 20210228626Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: ApplicationFiled: April 9, 2021Publication date: July 29, 2021Applicants: ABT Holding Company, OREGON HEALTH & SCIENCE UNIVERISTYInventors: Robert DEANS, Richard MAZIARZ, Magdalena KOVACSOVICS, Philip STREETER, Wouter VAN'T HOF
-
Publication number: 20210205359Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: ApplicationFiled: January 12, 2021Publication date: July 8, 2021Applicants: ABT Holding Company, OREGON HEALTH & SCIENCE UNIVERISTYInventors: Robert Deans, Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Wouter Van't Hof
-
Patent number: 11000546Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: GrantFiled: May 3, 2018Date of Patent: May 11, 2021Assignees: ATHERSYS, INC., OREGON HEALTH & SCIENCE UNIVERISTYInventors: Robert Deans, Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Wouter Van't Hof
-
Publication number: 20180318346Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: ApplicationFiled: May 3, 2018Publication date: November 8, 2018Applicants: ATHERSYS, INC., OREGON HEALTH & SCIENCE UNIVERISTYInventors: Robert DEANS, Richard MAZIARZ, Magdalena KOVACSOVICS, Philip STREETER, Wouter VAN'T HOF
-
Patent number: 9962407Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: GrantFiled: November 9, 2006Date of Patent: May 8, 2018Assignees: Athersys, Inc., Oregon Health and Science UniversityInventors: Robert Deans, Wouter Van't Hof, Richard Maziarz, Magdalena Kovacsovics, Philip Streeter
-
Publication number: 20180055881Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: ApplicationFiled: November 6, 2017Publication date: March 1, 2018Applicants: ATHERSYS, INC., OREGON HEALTH AND SCIENCE UNIVERSITYInventors: Richard MAZIARZ, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
-
Patent number: 9808485Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: GrantFiled: January 6, 2012Date of Patent: November 7, 2017Assignees: Athersys, Inc., Oregon Health And Science UniversityInventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
-
Publication number: 20150118193Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: ApplicationFiled: July 30, 2013Publication date: April 30, 2015Applicant: Oregon Health And Science UniversityInventors: Richard MAZIARZ, Magdalena KOVACSOVICS, Philip STREETER, Robert DEANS, Wouter VAN'T HOF
-
Publication number: 20140134137Abstract: The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential.Type: ApplicationFiled: November 1, 2013Publication date: May 15, 2014Applicant: ABT Holding CompanyInventor: Wouter Van't Hof
-
Publication number: 20140037596Abstract: The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in vascular endothelial cells. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to the endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential.Type: ApplicationFiled: October 10, 2013Publication date: February 6, 2014Applicant: ABT Holding CompanyInventors: Juliana Megan WODA, Wouter VAN'T HOF
-
Publication number: 20120135043Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: ApplicationFiled: January 6, 2012Publication date: May 31, 2012Inventors: Richard MAZIARZ, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
-
Patent number: 8147824Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: GrantFiled: November 9, 2005Date of Patent: April 3, 2012Assignees: Athersys, Inc., Oregon Health and Science UniversityInventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
-
Publication number: 20110020293Abstract: The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in vascular endothelial cells. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to the endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential.Type: ApplicationFiled: July 21, 2010Publication date: January 27, 2011Applicant: ABT Holding CompanyInventors: Juliana Megan Woda, Wouter Van't Hof
-
Publication number: 20110020292Abstract: The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential.Type: ApplicationFiled: July 21, 2010Publication date: January 27, 2011Applicant: ABT Holding CompanyInventor: Wouter Van't Hof
-
Publication number: 20060263337Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: ApplicationFiled: November 9, 2005Publication date: November 23, 2006Inventors: Richard Maziarz, Philip Streeter, Magdalena Kovacsovics, Robert Deans, Wouter Van't Hof